Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Detention and Banned Medical Devices, 18057-18058 [2019-08558]
Download as PDF
18057
Federal Register / Vol. 84, No. 82 / Monday, April 29, 2019 / Notices
Dated: April 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
include the FDA docket number found
in brackets in the heading of this
document.
[FR Doc. 2019–08609 Filed 4–26–19; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 4164–01–P
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Administrative
Detention and Banned Medical Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
[Docket No. FDA–2018–N–4465]
Administrative Detention and Banned
Medical Devices—21 CFR 800.55(g)(1),
(g)(2), and (k), 895.21(d), and 895.229(a)
OMB Control Number 0910–0114—
Extension
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 29,
2019.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0114. Also
ADDRESSES:
FDA has the statutory authority under
section 304(g) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C.
334(g)) to detain during established
inspections devices that are believed to
be adulterated or misbranded. Section
800.55 (21 CFR 800.55), on
administrative detention, includes
among other things certain reporting
requirements (§ 800.55(g)(1) and (2)) and
recordkeeping requirements
(§ 800.55(k)). Under § 800.55(g), an
appellant of a detention order must
show documentation of ownership if
devices are detained at a place other
than that of the appellant. Under
§ 800.55(k), the owner or other
responsible person must supply records
about how the devices may have
become adulterated or misbranded, in
addition to records of distribution of the
detained devices. These recordkeeping
requirements for administrative
detentions permit FDA to trace devices
for which the detention period expired
before a seizure is accomplished or
injunctive relief is obtained.
FDA also has the statutory authority
under section 516 of the FD&C Act (21
U.S.C. 360f) to ban devices that present
substantial deception or an
unreasonable and substantial risk of
illness or injury. Section 895.21 (21 CFR
895.21), on banned devices, contains
certain reporting requirements. Section
895.21(d) describes the procedures for
banning a device when the
Commissioner of Food and Drugs (the
Commissioner) decides to initiate such
a proceeding. Under 21 CFR 895.22, a
manufacturer, distributor, or importer of
a device may be required to submit to
FDA all relevant and available data and
information to enable the Commissioner
to determine whether the device
presents substantial deception,
unreasonable and substantial risk of
illness or injury, or unreasonable, direct,
and substantial danger to the health of
individuals.
During the past several years, there
has been an average of less than one
new administrative detention action per
year. Each administrative detention will
have varying amounts of data and
information that must be maintained.
In the Federal Register of December
21, 2018 (83 FR 65683), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses per
respondent
Number of
respondents
21 CFR section
Average
burden per
response
Total annual
responses
Total hours
Documentation of ownership—800.55(g) ............................
Banned devices reporting requirements—895.21(d)(8) and
895.22(a) ..........................................................................
1
1
1
25
25
26
1
26
16
416
Total ..............................................................................
........................
........................
........................
........................
441
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
khammond on DSKBBV9HB2PROD with NOTICES
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
21 CFR section
Records regarding device adulteration or misbranding and
records of distribution of detained devices—800.55(k) ...
1 There
Number of
records per
recordkeeper
1
Average
burden per
recordkeeping
Total annual
records
1
1
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
16:56 Apr 26, 2019
Jkt 247001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\29APN1.SGM
29APN1
20
Total hours
20
18058
Federal Register / Vol. 84, No. 82 / Monday, April 29, 2019 / Notices
Based on a review of the information
collection since our last request for
OMB approval, we have made no
adjustments to our burden estimate.
Dated: April 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–08558 Filed 4–26–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKBBV9HB2PROD with NOTICES
National Institute of Mental Health;
Notice of Workshop
Notice is hereby given of a workshop
convened by the Interagency Autism
Coordinating Committee (IACC).
The purpose of the 2019 IACC
Workshop, Addressing the Health
Outcome Needs of People with Autism
Spectrum Disorder (ASD), is to convene
a working group of the IACC that will
focus on the health outcome needs of
individuals with ASD. The working
group will use this workshop to discuss
health epidemiology, patient-provider
interactions, and co-occurring health
conditions that affect individuals with
ASD. The workshop will be open to the
public, will include time for public
comments, and will be accessible by
live webcast and conference call.
Name of Committee: Interagency
Autism Coordinating Committee (IACC).
Type of meeting: 2019 IACC
Workshop on Addressing the Health
Outcome Needs of People with Autism
Spectrum Disorder.
Date: Tuesday, May 21, 2019.
Time: 8:30 a.m. to 5:00 p.m. Eastern
Time.
Agenda: The workshop will focus the
discussion on the health and wellness of
individuals with Autism Spectrum
Disorder, including health
epidemiology, patient-provider
interaction, and the state of the science
on commonly co-occurring health
conditions affecting individuals on the
autism spectrum.
Place: Hilton Washington DC/
Rockville Hotel and Executive Meeting
Ctr, 1750 Rockville Pike, Rockville, MD
20852.
Webcast Live: https://
videocast.nih.gov.
Conference Call: 800–369–3119.
Access code: 5777378.
Cost: The meeting is free and open to
the public.
Registration: A registration web link
will be posted on the IACC website
(www.iacc.hhs.gov) prior to the meeting.
Pre-registration is recommended to
VerDate Sep<11>2014
16:56 Apr 26, 2019
Jkt 247001
expedite check-in. Seating in the
meeting room is limited to room
capacity and on a first come, first served
basis. Onsite registration will also be
available.
Deadlines: Notification of intent to
present oral comments: Friday, May 10,
2019, by 5:00 p.m. ET. Submission of
written/electronic statement for oral
comments: Tuesday, May 14, 2019, by
5:00 p.m. ET. Final deadline for
submission of written comments:
Tuesday, May 14, 2019, by 5:00 p.m. ET.
Webcast Live Feedback Public
comments: No preregistration required.
For instructions, see https://
iacc.hhs.gov/meetings/iacc-meetings/
live-feedback.shtml. For IACC public
comment guidelines, please see: https://
iacc.hhs.gov/meetings/publiccomments/guidelines/.
Access: Twinbrook Metro Station
(Red Line).
Contact Person: Ms. Angelice
Mitrakas, Office of Autism Research
Coordination, National Institute of
Mental Health, NIH, 6001 Executive
Boulevard, Room 7218, Bethesda, MD
20892–9669, Phone: 301–435–9269,
Email: IACCPublicInquiries@
mail.nih.gov.
Public Comments: The IACC invites
oral and written public-related
comments relevant to the topic of the
workshop. Individuals interested in
presenting oral comments must notify
the Contact Person listed on this notice
by 5:00 p.m. ET on Friday, May 10,
2019, with their request to present oral
comments at the meeting, and a written/
electronic copy of the oral presentation/
statement must be submitted by 5:00
p.m. ET on Tuesday, May 14, 2019.
A limited number of slots for oral
comment are available and will be
assigned on a first come, first serve
basis. Only one representative of an
organization will be allowed to present
oral comments at this meeting; other
representatives of the same group may
provide written comments. If the oral
comment session is full, individuals
who could not be accommodated are
welcome to provide written comments
instead. Comments to be read or
presented in the meeting will be
assigned a 3-minute time slot, but a
longer version may be submitted in
writing for the record. Commenters
going beyond their allotted time in the
meeting may be asked to conclude
immediately to allow other comments
and presentations to proceed on
schedule.
Any interested person may submit
written public comments to the IACC
prior to the meeting by emailing the
comments to IACCPublicInquiries@
mail.nih.gov, or by submitting
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
comments at the web link: https://
iacc.hhs.gov/meetings/publiccomments/submit/index.jsp by 5:00
p.m. ET on Tuesday, May 14, 2019. The
comments should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
NIMH anticipates written public
comments received by 5:00 p.m. ET on
Tuesday, May 14, 2019, will be
presented to the working group prior to
the workshop. Any written comments
received after the by 5:00 p.m. ET on
Tuesday, May 14, 2019 deadline
through Monday, May 20, 2019, will be
provided to the working group either
before or after the meeting, depending
on the volume of comments received
and the time required to process them
in accordance with privacy regulations
and other applicable Federal policies.
All written public comments and oral
public comment statements received by
the deadlines for both oral and written
public comments will be provided to
the IACC for their consideration and
will become part of the public record.
Attachments of copyrighted
publications are not permitted, but web
links or citations for any copyrighted
works cited may be provided.
Individuals may also submit public
comments to the IACC via a Live
Feedback Form accessible from the
webcast page on the day of the meeting
from 9:00 a.m. ET to 11:00 a.m. ET. No
pre-registration required. The link will
be accessible on the NIH Videocast
website and instructions are available
on the IACC website: https://
iacc.hhs.gov/meetings/iacc-meetings/
live-feedback.shtml This format is best
suited for brief questions and comments
for the IACC. Submissions will be
provided to the IACC and will become
a part of the public record.
In the 2009 IACC Strategic Plan, the
IACC listed the ‘‘Spirit of Collaboration’’
as one of its core values, stating that,
‘‘We will treat others with respect, listen
to diverse views with open minds,
discuss submitted public comments,
and foster discussions where
participants can comfortably offer
opposing opinions.’’ In keeping with
this core value, the IACC and the NIMH
Office of Autism Research Coordination
(OARC) ask that members of the public
who provide public comments or
participate in meetings of the IACC also
seek to treat others with respect and
consideration in their communications
and actions, even when discussing
issues of genuine concern or
disagreement.
Remote Access: The meeting will be
open to the public through a conference
call phone number and webcast live on
E:\FR\FM\29APN1.SGM
29APN1
Agencies
[Federal Register Volume 84, Number 82 (Monday, April 29, 2019)]
[Notices]
[Pages 18057-18058]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-08558]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-4465]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Administrative
Detention and Banned Medical Devices
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by May 29,
2019.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to [email protected]. All
comments should be identified with the OMB control number 0910-0114.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Administrative Detention and Banned Medical Devices--21 CFR
800.55(g)(1), (g)(2), and (k), 895.21(d), and 895.229(a)
OMB Control Number 0910-0114--Extension
FDA has the statutory authority under section 304(g) of the Federal
Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 334(g)) to detain
during established inspections devices that are believed to be
adulterated or misbranded. Section 800.55 (21 CFR 800.55), on
administrative detention, includes among other things certain reporting
requirements (Sec. 800.55(g)(1) and (2)) and recordkeeping
requirements (Sec. 800.55(k)). Under Sec. [thinsp]800.55(g), an
appellant of a detention order must show documentation of ownership if
devices are detained at a place other than that of the appellant. Under
Sec. [thinsp]800.55(k), the owner or other responsible person must
supply records about how the devices may have become adulterated or
misbranded, in addition to records of distribution of the detained
devices. These recordkeeping requirements for administrative detentions
permit FDA to trace devices for which the detention period expired
before a seizure is accomplished or injunctive relief is obtained.
FDA also has the statutory authority under section 516 of the FD&C
Act (21 U.S.C. 360f) to ban devices that present substantial deception
or an unreasonable and substantial risk of illness or injury. Section
895.21 (21 CFR 895.21), on banned devices, contains certain reporting
requirements. Section 895.21(d) describes the procedures for banning a
device when the Commissioner of Food and Drugs (the Commissioner)
decides to initiate such a proceeding. Under 21 CFR 895.22, a
manufacturer, distributor, or importer of a device may be required to
submit to FDA all relevant and available data and information to enable
the Commissioner to determine whether the device presents substantial
deception, unreasonable and substantial risk of illness or injury, or
unreasonable, direct, and substantial danger to the health of
individuals.
During the past several years, there has been an average of less
than one new administrative detention action per year. Each
administrative detention will have varying amounts of data and
information that must be maintained.
In the Federal Register of December 21, 2018 (83 FR 65683), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Documentation of ownership-- 1 1 1 25 25
800.55(g)......................
Banned devices reporting 26 1 26 16 416
requirements--895.21(d)(8) and
895.22(a)......................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 441
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR section Number of records per Total annual per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
Records regarding device 1 1 1 20 20
adulteration or misbranding and
records of distribution of
detained devices--800.55(k)....
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 18058]]
Based on a review of the information collection since our last
request for OMB approval, we have made no adjustments to our burden
estimate.
Dated: April 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-08558 Filed 4-26-19; 8:45 am]
BILLING CODE 4164-01-P